Fortrea Holdings (FTRE) Net Income Quarterly: History & Chart

Fortrea Holdings Inc.(FTRE)

Biotechnology · Durham, NC

$20.00+0.60 (+3.09%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Fortrea Holdings Inc.

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Durham, NC

14,000 employees

www.fortrea.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Anshul Thakral

View full financials

Quarterly Net Income

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly net income is ($13.20M) with QoQ Growth of +44.07%. Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.

Net Income TTM|Net Income CAGR|Profit Margin|Financials

Quarterly Net Income

FTRE Quarterly Net Income

$-13.20M

Reported quarterly net income; no daily interpolation. Q2 FY2026 (2026-06-30): $-13.20M.

-140.62% over 10Y

FTRE P/E Ratio

Full P/E Ratio page

P/E Ratio

FTRE P/E Ratio Chart

N/A

FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-03T00:15:29.228Z. Historical observations retain their original dates. Historical series through 2024-03-13.

FTRE Earnings Yield

Full Earnings Yield page

Earnings Yield

FTRE Earnings Yield Chart

N/A

Unrounded diluted TTM EPS / FMP quote price × 100 Quote observation: 2026-10-03T00:15:29.228Z. Historical observations retain their original dates. Historical series through 2024-03-13.

Quarterly Net Income History

Period	Quarterly Net Income	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($13.20M)	+44.07%	+96.48%
Q1 FY2026Period end 2026-03-31	($23.60M)	+27.38%	+95.81%
Q4 FY2025Period end 2025-12-31	($32.50M)	(104.40%)	+46.90%
Q3 FY2025Period end 2025-09-30	($15.90M)	+95.76%	+43.01%
Q2 FY2025Period end 2025-06-30	($374.90M)	+33.40%	(170.88%)
Q1 FY2025Period end 2025-03-31	($562.90M)	(819.77%)	(457.33%)
Q4 FY2024Period end 2024-12-31	($61.20M)	(119.35%)	(70.00%)
Q3 FY2024Period end 2024-09-30	($27.90M)	+79.84%	(99.29%)
Q2 FY2024Period end 2024-06-30	($138.40M)	(37.03%)	N/A
Q1 FY2024Period end 2024-03-31	($101.00M)	(180.56%)	N/A
Q4 FY2023Period end 2023-12-31	($36.00M)	(157.14%)	N/A
Q3 FY2023Period end 2023-09-30	($14.00M)	N/A	N/A
Q2 FY2023Period end 2023-06-30	$30.80M	+146.40%	(53.61%)
Q1 FY2023Period end 2023-03-31	$12.50M	(53.18%)	(61.54%)
Q4 FY2022Period end 2022-12-31	$26.70M	(55.94%)	N/A
Q3 FY2022Period end 2022-09-30	$60.60M	(8.73%)	N/A
Q2 FY2022Period end 2022-06-30	$66.40M	+104.31%	N/A
Q1 FY2022Period end 2022-03-31	$32.50M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.